Increased F2-isoprostanes in Alzheimer's disease:: evidence for enhanced lipid peroxidation in vivo

被引:345
|
作者
Praticò, D
Lee, VMY
Trojanowski, JQ
Rokach, J
Fitzgerald, GA
机构
[1] Univ Penn, Sch Med, Ctr Expt Therapeut, Philadelphia, PA 19104 USA
[2] Univ Penn, Sch Med, Ctr Neurodegenerat Dis Res Pathol & Lab Med, Philadelphia, PA 19104 USA
[3] Florida Inst Technol, Claude Pepper Inst, Melbourne, FL 32901 USA
[4] Florida Inst Technol, Dept Chem, Melbourne, FL 32901 USA
来源
FASEB JOURNAL | 1998年 / 12卷 / 15期
关键词
oxidative stress; schizophrenia; temporal lobes; neurofibrillary tangles;
D O I
10.1096/fasebj.12.15.1777
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Alzheimer's disease (AD) includes a group of dementing neurodegenerative disorders that have diverse etiologies but the same hallmark brain lesions. Since oxidative stress may play a role in the pathogenesis of AD and isoprostanes are chemically stable peroxidation products of arachidonic acid, we measured both iPF(2 alpha)-III and iPF(2 alpha)-VI using gas chromatography-mass spectrometry in AD and control brains. The levels of both isoprostanes, but not of 6-keto PGF(1 alpha), an index of prostaglandin production, were markedly elevated in both frontal and temporal poles of AD brains compared to the corresponding cerebella. Levels were also elevated compared to corresponding areas of brains from patients who had died with schizophrenia or Parkinson's disease or from nonneuropsychiatric disorders, iPF(2 alpha) - IV, but not iPF(2 alpha)-III, levels were higher in ventricular CSF of AD brains relative to the non-AD brains. These data suggest that specific isoprostane analysis may reflect increased oxidative stress in AD.
引用
收藏
页码:1777 / 1783
页数:7
相关论文
共 50 条
  • [1] Increased urinary F2-isoprostanes levels in the patients with Alzheimer's disease
    Kim, KM
    Jung, BH
    Paeng, KJ
    Kim, I
    Chung, BC
    [J]. BRAIN RESEARCH BULLETIN, 2004, 64 (01) : 47 - 51
  • [2] Biomarkers of Alzheimer's disease: F2-isoprostanes
    Pratico, D
    [J]. NEUROBIOLOGY OF AGING, 2004, 25 : S5 - S5
  • [3] Peripheral F2-isoprostanes and F4-neuroprostanes are not increased in Alzheimer's disease
    Montine, TJ
    Quinn, JF
    Milatovic, D
    Silbert, LC
    Dang, T
    Sanchez, S
    Terry, E
    Roberts, LJ
    Kaye, JA
    Morrow, JD
    [J]. ANNALS OF NEUROLOGY, 2002, 52 (02) : 175 - 179
  • [4] Lipid peroxidation - measured by plasma F2-Isoprostanes - and obesity
    Dietrich, M
    Block, G
    Packer, L
    Morrow, JD
    [J]. FREE RADICAL BIOLOGY AND MEDICINE, 2001, 31 : S85 - S85
  • [5] F2-isoprostanes as indices of lipid peroxidation in inflammatory diseases
    Praticò, D
    Rokach, J
    Lawson, J
    FitzGerald, GA
    [J]. CHEMISTRY AND PHYSICS OF LIPIDS, 2004, 128 (1-2) : 165 - 171
  • [6] F2-isoprostanes:: sensitive and specific non-invasive indices of lipid peroxidation in vivo
    Praticò, D
    [J]. ATHEROSCLEROSIS, 1999, 147 (01) : 1 - 10
  • [7] Increased urinary F2-isoprostanes in patients with Crohn's disease
    Cracowski, JL
    Bonaz, B
    Bessard, G
    Bessard, J
    Anglade, C
    Fournet, J
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2002, 97 (01): : 99 - 103
  • [8] Enhanced urinary F2-isoprostanes in patients with Crohn's disease
    Bonaz, B
    Cracowski, JL
    Bessard, J
    Anglade, C
    Bessard, G
    Fournet, J
    [J]. GASTROENTEROLOGY, 2001, 120 (05) : A186 - A186
  • [9] Association between low serum enterolactone and increased plasma F2-isoprostanes, a measure of lipid peroxidation
    Vanharanta, M
    Voutilainen, S
    Nurmi, T
    Kaikkonen, J
    Roberts, LJ
    Morrow, JD
    Adlercreutz, H
    Salonen, JT
    [J]. ATHEROSCLEROSIS, 2002, 160 (02) : 465 - 469
  • [10] F2-isoprostanes as biomarkers of late-onset Alzheimer's disease
    Montine, Thomas J.
    Quinn, Joseph
    Kaye, Jeffrey
    Morrow, Jason D.
    [J]. JOURNAL OF MOLECULAR NEUROSCIENCE, 2007, 33 (01) : 114 - 119